Ancilia Biosciences Announces Closing of $4.2 Million Financing Ancilia raised $4.2M to leverage CRISPR’s natural function to create bacterial therapies with immunity against the viruses that limit their effectiveness.

Final Results for the year ended 31 December 2020 Leeds, UK, April 01, 2021 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the...